$LUCD 💥BOOM💥 Medicare is now paying for EsoGuard at $1,938 per test under PLA 0114U. Texas lab collecting now. California lab waits on the revised MolDX LCD. Same playbook as Cologuard: FDA-cleared DNA test, office-based collection, Medicare coverage as the unlock. When CMS covered Cologuard in Oct 2014 at $502 a test, EXAS jumped nearly 40% overnight and its market cap went from about $1B to over $2B in weeks. Test volume went from 4,000 in 2014 to 244,000 in 2016 to 934,000 in 2018 & revenue hit $454M that year, up 71%. By 2021 EXAS was a $26B company. EsoGuard’s TAM is $60B with roughly 30M at-risk GERD patients. Over 50,000 tests run to date, claims paid approaching $140M, gross margins above 90%. (Unheard of 😳) CMS final gapfill lands in Nov. $15M Series C clos
在 X 查看 ↗